Ziopharm falls on palifosfamide delay

Ziopharm Oncology Inc. (NASDAQ:ZIOP) fell $1.43 (29%) to $3.42 on Monday after delaying the start of the Phase III PICASSO III trial of palifosfamide in metastatic soft tissue sarcoma to next quarter ...